- Home
- MYGN
MYGN
Myriad Genetics Inc.
as 04-23-2025 4:00pm EST
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 744.7M | IPO Year: | 1995 |
| Target Price: | $20.17 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Hold | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.35 - $29.30 | Next Earning Date: | 05-06-2025 |
| Revenue: | $837,600,000 | Revenue Growth: | 11.21% |
| Revenue Growth (this year): | 2.99% | Revenue Growth (next year): | 8.36% |
Latest Myriad Genetics Inc. News
MYGN Breaking Stock News: Dive into MYGN Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
GlobeNewswire
2 days ago
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
Argus Research
8 days ago
MYGN: What does Argus have to say about MYGN?
TipRanks
9 days ago
Myriad Genetics price target lowered to $9 from $11 at BofA
MT Newswires
15 days ago
Guggenheim Downgrades Myriad Genetics to Neutral From Buy
Argus Research
15 days ago
MYGN: Lowering target price to $8.00
GlobeNewswire
15 days ago
Myriad Genetics Announces Inducement Awards
GlobeNewswire
17 days ago
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
Compare MYGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYGN Myriad Genetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.